| Diabetes Mellitus, Non-Insulin-Dependent
Atorvaliq vs Lipitor
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Atorvaliq vs Lipitor with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLipitor has a higher rate of injection site reactions vs Atorvaliq based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lipitor but not Atorvaliq, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Atorvaliq
Lipitor
At A Glance
Oral
Daily
HMG-CoA reductase inhibitor
Oral
Daily
HMG-CoA reductase inhibitor (statin)
Indications
- Coronary heart disease
- Diabetes Mellitus, Non-Insulin-Dependent
- Heart failure
- Hyperlipidemia
- Hypercholesterolemia, Familial
- Hypertriglyceridemia
- Myocardial Infarction
- Cerebrovascular accident
- Stable angina
- Diabetes Mellitus, Non-Insulin-Dependent
- Congestive heart failure
- Hyperlipidemia
- Familial hypercholesterolemia - heterozygous
- Homozygous Familial Hypercholesterolemia
- Hyperlipoproteinemia Type III
- Hypertriglyceridemia
Dosing
Coronary heart disease, Diabetes Mellitus Non-Insulin-Dependent, Heart failure, Hyperlipidemia, Hypertriglyceridemia 10 or 20 mg once daily orally on an empty stomach; dosage range 10-80 mg once daily; patients requiring LDL-C reduction >45% may start at 40 mg once daily.
Hypercholesterolemia, Familial (HeFH, pediatric >= 10 years) 10 mg once daily orally on an empty stomach; dosage range 10-20 mg once daily.
Hypercholesterolemia, Familial (HoFH, pediatric >= 10 years) 10-20 mg once daily orally on an empty stomach; dosage range 10-80 mg once daily.
Myocardial Infarction, Cerebrovascular accident, Stable angina, Diabetes Mellitus Non-Insulin-Dependent, Congestive heart failure, Hyperlipidemia, Hyperlipoproteinemia Type III, Hypertriglyceridemia 10 or 20 mg once daily starting; range 10-80 mg once daily; patients requiring LDL-C reduction >45% may start at 40 mg once daily; oral.
Familial hypercholesterolemia - heterozygous Adults: 10 or 20 mg once daily, range 10-80 mg once daily; pediatric patients aged >=10 years: 10 mg once daily starting, range 10-20 mg once daily; oral.
Homozygous Familial Hypercholesterolemia Adults: 10 or 20 mg once daily, range 10-80 mg once daily; pediatric patients aged >=10 years: 10-20 mg once daily starting, range 10-80 mg once daily; oral.
Contraindications
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to atorvastatin or any excipients in ATORVALIQ
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to atorvastatin or any excipient in Lipitor
Adverse Reactions
Most common (>=2%) Nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, pharyngolaryngeal pain
Serious Myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, increases in HbA1c and fasting serum glucose
Postmarketing Pancreatitis, fatigue, fatal and non-fatal hepatic failure, anaphylaxis, tendon rupture, rhabdomyolysis, myositis, dizziness, peripheral neuropathy, cognitive impairment, depression, interstitial lung disease, angioneurotic edema, bullous rashes
Most common (>=2%) Nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, pharyngolaryngeal pain
Serious Myopathy and rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, increases in HbA1c and fasting serum glucose
Postmarketing Pancreatitis, fatigue, fatal and non-fatal hepatic failure, anaphylaxis, tendon rupture, rhabdomyolysis, myositis, dizziness, peripheral neuropathy, cognitive impairment, myasthenia gravis exacerbation, depression, interstitial lung disease, angioneurotic edema, bullous rashes
Pharmacology
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, a cholesterol precursor; it lowers plasma cholesterol and LDL levels by inhibiting hepatic cholesterol synthesis and increasing hepatic LDL receptor expression.
Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of cholesterol; it lowers plasma LDL cholesterol and lipoprotein levels by inhibiting hepatic cholesterol synthesis and upregulating LDL receptor expression on hepatic cell surfaces.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
No coverage data available for Atorvaliq.
Lipitor
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (1/12)
UnitedHealthcare
No coverage data available for Atorvaliq.
Lipitor
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
No coverage data available for Atorvaliq.
Lipitor
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Atorvaliq.
No savings programs available for Lipitor.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AtorvaliqView full Atorvaliq profile
LipitorView full Lipitor profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.